SAB Biotherapeutics
is a South Dakota-based biopharmaceutical company that develops and commercializes immunotherapies to treat infectious diseases... Read moreSAB Biotherapeutics
is a South Dakota-based biopharmaceutical company that develops and commercializes immunotherapies to treat infectious diseases... Read more
News
Apr 22, 2026
GlobalNewswire
Press Release: SAB Biotherapeutics : SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
Nov 14, 2025
Owler
SAB Biotherapeutics, Inc.: SAB Biotherapeutics's revenue had no change from Jun 2025 to Sep 2025
Mar 31, 2025
Owler
SAB Biotherapeutics, Inc.: SAB Biotherapeutics's revenue changed from $1.51M in Sep 2024 to $1.32M in Dec 2024
Jan 28, 2025
centralcharts
Press Release: SAB Biotherapeutics : SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
Oct 31, 2024
GlobeNewswire
Press Release: SAB Biotherapeutics : SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Aug 09, 2024
Owler
SAB Biotherapeutics, Inc.: SAB Biotherapeutics's revenue changed from $2.60M in Mar 2024 to $2.78M in Jun 2024
Aug 01, 2024
Citybizlist
SAB Biotherapeutics: SAB BIO Appoints Lucy To as Chief Financial Officer
May 30, 2024
StreetInsider
Press Release: SAB Biotherapeutics : SAB Biotherapeutics Announces Departure of Chief Financial Officer
May 20, 2024
Owler
SAB Biotherapeutics, Inc.: SAB Biotherapeutics's revenue changed from $2.24M in Dec 2023 to $2.60M in Mar 2024
Apr 08, 2024
Benzinga
SAB Biotherapeutics: SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics Competitors
1
2
3
4
5
6
7
8
9
10